logo
Argentines in Rome Pray for a Pope Who's One of Their Own

Argentines in Rome Pray for a Pope Who's One of Their Own

New York Times04-03-2025

On Sunday evening, Mariarosa Cavañas lit a candle in front of a small chapel in the Church of Santa Maria Addolorata — the national church of Argentina in Rome — where a photo of Pope Francis was affixed on a dais next to a prayer for his good health. On the back wall of the chapel sat a small statue of Our Lady of Lujàn, the patron saint of Argentina, Paraguay and Uruguay, and a prayer entrusting Francis to her care.
'I hope he gets better,' said Ms. Cavañas, an Argentine who works as a nurse auxiliary in Rome. She was among the dozens of faithful who had flocked to the church for a Mass that brings Rome's Argentine community together on the first Sunday of every month. This Sunday, their ailing compatriot Francis was very much on everyone's mind, and in their prayers.
Francis has been in a Rome hospital with pneumonia and other infections since Feb. 14. On Tuesday evening, the Vatican said that Francis' condition was stable after suffering two acute respiratory episodes the previous day.
'I am very sad, and I've been praying for him,' said Marcela Perez, who works for a institute that houses six nuns in Rome. 'All of Argentina is praying for the pope.'
Millions around the world have been offering prayers for Francis since he entered the hospital. But members of the Argentine community that meets at the church of Santa Maria Addolorata, built a century ago by Argentine bishops, said they felt particularly close to him.
About 1,200 Argentines live in Rome, according to the Rome-based IDOS study and research center, which tracks immigration in Italy. Aptly, the church is in Piazza Buenos Aires, which borders some of Rome's most well-heeled neighborhoods.
Dozens of get-well wishes were scribbled — nearly all in Spanish — in a guest book in the chapel. The Rev. Fernando Laguna, the church's rector, said it would be delivered to Pope Francis at the Policlinico Agostino Gemelli where he is being treated.
Before he became Pope Francis, Cardinal Jorge Bergoglio used to occasionally say Mass at the church, recalled Mary Cuartas, a retired dentist.
'We always pray for the pope,' said Father Laguna, but the prayers have 'intensified' since Francis was admitted to the hospital. In front of the main altar, next to a statue of Our Lady of Lujàn, was another photo of Francis with the entreaty 'For the Health of the Holy Father.'
Francis remains closely attached to his native country. He is a fan of San Lorenzo, a Buenos Aires soccer team — though he hasn't seen a game on television for decades, having vowed to never again watch television after being 'deeply offended' by a 'sordid scene' he saw onscreen in 1990, he said in his autobiography, 'Hope.'
But he added that he was kept informed about the team thanks to a 'Swiss guardsman who leaves the results and league tables on my desk.' In 'Hope,' which was published in January, Francis recounts that he has kept in touch with several of his childhood friends, who often visit him if they pass through Rome.
'There's always a lot of Argentines around,' said Archbishop Paul Gallagher, the Vatican's foreign minister. 'He sometimes assumes a personal responsibility,' remaining in touch with Argentine clerics and nuns in far-flung places.
On a physically grueling 11-day trip to the Asia-Pacific region last September, Francis flew 600 miles to Vanimo, a remote outpost of Papua New Guinea, to spend an afternoon with a group of missionaries from Argentina and local Catholics. The priests served him mate, a traditional herbal drink that is common in South America.
Since the beginning of the war in Gaza, Francis has been in near nightly contact with a parish led by an Argentine priest in the enclave, although the calls became less frequent after he entered hospital.
Francis also hasn't lost his taste for Argentine food.
Angel Moavro, one of the owners of Baires, an Argentine restaurant in downtown Rome, said Francis' compatriots often came to buy homemade desserts to bring to the pope, including alfajores, a popular sandwich cookie, churros — 'which are Spanish but we eat them a lot in Argentina,' Mr. Moavro said — and budin de pan, a bread pudding.
Since his hospitalization began, Francis' normally outspoken voice had all but disappeared, save for short messages via Angelus prayers on Sundays, and it was sorely missed, said Mr. Moavro. 'We really need him these days' to help mediate, he said, referring to the explosive confrontation at the White House between President Trump and President Volodymyr Zelensky of Ukraine.
'Certainly, once he's back he's going to have to take more care of himself,' he said.
Ms. Cuartas said she could hardly wait until Francis returned to Casa Santa Marta, the guesthouse inside the Vatican where the pope has chosen to live. But then, she added, 'he has to go visit Argentina.'
A visit, or rather lack there of, to his homeland has become a sore point for many Argentines.
John Paul II went to Poland, his native home, eight times during his papacy. Benedict XVI went to Germany, where he was born, three times. But in the 12 years of his papacy, Francis has not set foot in Argentina.
'A trip to Argentina is a pending subject,' said Elisabetta Piqué, an Argentine journalist and biographer of Pope Francis. She said she believed Francis had always felt that a trip home might be politically manipulated by whichever leader happened to be in charge at the time. 'So he's kept putting it off, and obviously this has created a lot of frustration in Argentina,' she said.
Another biographer, Austen Ivereigh, said Francis had told him that he wanted to go to Argentina only 'if the visit would be a source of unity and healing in a very fractured and divided society,' and that it remained unclear whether that would be the case. 'Argentina is famous for its polarized culture' he said.
'It's always been complex' to plan a trip to Argentina, Mr. Ivereigh said, adding that Francis also believed that other countries had needed a papal visit more than his native country.
After Mass on Sunday, as they do each month, the dozens of Argentine expats gathered in the church hall to eat empanadas made by volunteers.
Federico Gatti, who works in risk assessment for an American import export company, said the Argentine community in Rome saw Francis as one of their own. 'For us, it's as though our grandfather is ill, we want him to get better,' he said. 'So one prays, hopes he will get better, in the hope that he will regain his forces and the support of all the church on this path.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Medically tailored nutrition can help make America healthy
Medically tailored nutrition can help make America healthy

The Hill

timean hour ago

  • The Hill

Medically tailored nutrition can help make America healthy

Chronic disease is a threat not only to Americans' physical health but also to the nation's financial health. Conditions like heart disease, cancer, diabetes and kidney failure account for trillions of dollars in annual health care spending and are among the leading causes of death in the U.S. The growing consensus is clear that our health care system needs better solutions to manage chronic diseases. One promising tool is surprisingly simple: food. But not just any food. We need nutritious, locally sourced, medically tailored meals — food-based interventions designed by registered dietitian nutritionists specifically for chronically ill Americans. These medically tailored meals are proven to improve health outcomes, reduce hospitalizations and lower health care costs. Just as important, they can reduce patients' dependency on medications, making health care more effective and affordable. At the Boston-based nonprofit I lead, we have seen firsthand how medically tailored meals can transform lives. One of our clients, for example, reduced his daily medications from 14 to just four after enrolling in our program. This is what we mean when we say 'food is medicine' — food, either alone or in conjunction with pharmaceuticals, can help patients become and stay healthier. These meals are not only about nourishment. They are about addressing the root causes of chronic diseases while offering real cost savings. Medically tailored meals prioritize nutrition, treating the underlying causes of disease, not just symptoms. They reduce dependence on medication, leading to fewer prescriptions and better health outcomes. These meals prioritize fresh ingredients over processed foods, with a commitment to quality local food. They lead to immediate cost savings, with reductions in hospitalizations and medical costs. And they support local businesses, strengthening local farms and fishing industries through prioritization of regional sourcing. Does it work? The evidence is clear. Studies published in JAMA and Health Affairs show that medically tailored meals reduce hospitalizations by 49 percent and emergency room visits by 70 percent. They have also been shown to lower total medical costs by a remarkable 16 percent. Another recent study published in Health Affairs estimates that a nationwide rollout of medically tailored meals could save $32 billion annually. In a time of policy uncertainty, one thing is clear: 'Food is medicine' is a bipartisan opportunity to transform health care. The Make America Healthy Again movement is dedicated to reducing the burden of chronic diseases, decreasing reliance on pharmaceuticals and integrating nutrition into health care. The Senate MAHA Caucus is already focused on improving access to high-quality, nutrient-dense foods and addressing the root causes of disease. Congress should act now to expand medically tailored nutrition for veterans, older Americans and people with disabilities — groups who stand to benefit the most. Let us seize this moment and make medically tailored nutrition a central part of making America healthy again. David B. Waters is the CEO of Community Servings, a Boston-based nonprofit provider of medically tailored meals and nutrition services, and founder of the AMPL Institute.

Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs
Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs

Yahoo

time2 hours ago

  • Yahoo

Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs

Philip Morris International Inc., a leading tobacco company, is committed to becoming a 100% smoke-free entity. By March 2025, 42% of revenue was from smoke-free products like IQOS and ZYN. The firm is advancing digital transformation and tech initiatives to enhance health-focused and prescription products. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Philip Morris International Inc. - 2025" company profile has been added to offering. The report provides insights into the Philip Morris International's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Philip Morris International Inc. (Philip Morris) is a US-based multinational tobacco company. It produces cigarettes and a variety of smoke-free products, including e-vapor, heated tobacco, and oral smokeless products. Philip Morris aims to become a 100% smoke-free products company in the near future. As of March 31, 2025, smoke-free products accounted for 42% of Philip Morris' overall revenue. The company is also focusing on developing and commercializing oral and inhaled consumer health & wellness products, as well as inhaled prescription products for cardiovascular emergencies and pain management. IQOS and ZYN are the leading smoke-free brands of the company, while Marlboro, Parliament, Chesterfield, L&M and Philip Morris are the leading cigarette report provides information and insights into Philip Morris' tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives covering partnerships and product launches. Insights on each technology initiative including technology theme, objective, and benefits. Details of estimated ICT budgets. Reasons to Buy Gain insights into Philip Morris' tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and other Innovation Programs Technology Focus Technology Initiatives Venture Arm: PM Equity Partner Partnerships Network Map ICT Budget and Contracts Key Executives For more information about this company profile visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

Yahoo

time3 hours ago

  • Yahoo

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca and Third Harmonic Bio, as well as updates from UCB, UroGen Pharma and Insmed that you may have missed. AstraZeneca on Friday formed a new collaboration with Shijiazhuang City, China-based CSPC Pharmaceutical Group, this time to use the firm's AI technology to discover oral drugs for immunological diseases and other unspecified chronic conditions. CSPC will get $110 million in upfront cash and is eligible to receive up to $5.2 billion in additional development and sales milestones. The alliance builds on a 2024 deal that handed AstraZeneca an oral, lipid-lowering therapy, and deepens the British drugmaker's investment in China. In March, the company committed $2.5 billion to a research and development center in Beijing and formed collaborations with three China-based biotechs. — Ben Fidler Belgian drugmaker UCB said on Thursday that it plans to build a new biologics manufacturing plant in the U.S. UCB is currently running a "feasibility study" to determine the ideal U.S. location for the coming facility, but said in a statement that, once operational, it should create about 300 jobs in biologics manufacturing and have an economic impact of around $5 billion. The company currently employs close to 2,000 workers in the U.S. — Ben Fidler Stockholders of Third Harmonic Bio have voted in support of a liquidation plan expected to see them recoup anywhere from $5.30 to $5.44 for each share they own. The company also said Thursday that it's beginning an auction for an experimental drug for chronic hives that's ready for Phase 2 testing. Proceeds from that auction, as well as sales of any other remaining assets, could boost stockholder payouts beyond current estimates. Third Harmonic raised $185 million in a 2022 initial public offering, but its share price plummeted shortly afterwards following a clinical setback. — Ben Fidler Insmed has raised $750 million in a public stock offering, quickly cashing in on positive Phase 2 study results that pushed its market value past $16 billion. The company on Wednesday sold 7,812,500 shares of its common stock at $96 apiece, raising more than it initially projected. Insmed shares climbed by a third this week after mid-stage results indicated its experimental drug could be superior to an inhalable pulmonary arterial hypertension medicine that's sold by United Therapeutics and could reach almost $2 billion in sales this year. The company expects to start a pair of Phase 3 trials later this year and early next. — Ben Fidler The Food and Drug Administration bypassed the advice of one of its expert panels in approving a drug Urogen Pharma has been developing for a form of bladder cancer. The therapy, a formulation of the chemotherapy mitomycin, was cleared on Thursday and will be sold as Zusduri for a recurrent type of non-muscle invasive bladder cancer. FDA advisers last month determined by a slim, 5-4 margin, that the drug's benefits didn't outweigh the risks of treatment. UroGen shares surged more than 60% since the announcement. — Ben Fidler Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store